D
Dan Aderka
Researcher at Tel Aviv University
Publications - 119
Citations - 6165
Dan Aderka is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Tumor necrosis factor alpha & Receptor. The author has an hindex of 33, co-authored 116 publications receiving 5900 citations. Previous affiliations of Dan Aderka include Weizmann Institute of Science & Northwestern University.
Papers
More filters
Journal ArticleDOI
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.
TL;DR: It is reported here that in the presence of low concentrations of the sTNF-Rs, effects of TNF whose induction depend on prolonged treatment with this cytokine are augmented, reflecting an attenuation by the sST NF-Rs of spontaneous TNF activity decay.
Journal ArticleDOI
A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.
TL;DR: It is suggested that this protein blocks the function of TNF by competing for TNF with the TNF receptor and not by interacting with the target cell.
Journal ArticleDOI
Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.
Yaron Nophar,Oliver Kemper,Cord Brakebusch,H Englemann,R Zwang,Dan Aderka,H Holtmann,David Wallach +7 more
TL;DR: The soluble forms of the TNF‐Rs are structurally identical to the extracellular cytokine binding domains of these receptors and are consistent with the notion that the soluble forms are, at least partly, derived from the same transcripts that encode the cell surface receptors.
Journal ArticleDOI
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.
Andrew P. Cope,Dan Aderka,Michael Doherty,H Engelmann,Deena L. Gibbons,Adrian Jones,Fionula M. Brennan,Ravinder Nath Maini,David Wallach,Marc Feldmann +9 more
TL;DR: Evaluation of serially obtained serum samples suggested that sTNF-R may be a useful parameter for monitoring RA disease activity and determination of SF levels could be of diagnostic value.
Journal ArticleDOI
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
Talia Golan,Zaheer S. Kanji,Ron Epelbaum,N Devaud,N Devaud,Efrat Dagan,Spring Holter,Spring Holter,Dan Aderka,Dan Aderka,Shani Paluch-Shimon,Shani Paluch-Shimon,Brett A Kaufman,Brett A Kaufman,Ruth Gershoni-Baruch,David W. Hedley,Malcolm J. Moore,Eitan Friedman,Steven Gallinger,Steven Gallinger +19 more
TL;DR: Superior OS was observed for advanced-disease BRCA-associated PDAC with platinum exposure, observed for patients with stage 3/4 treated with platinum vs those treated with non-platinum chemotherapies.